Establishment of novel immunotherapy against malignant mesothelioma
| Project/Area Number |
23790185
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
ABE Shinji 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 助教 (00403717)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | オーダーメード医療 / トランスレーショナルリサーチ / 癌抗原 / 抗体療法 / 悪性胸膜中皮腫 / 腫瘍特異的免疫療法 / HM1.24 / ADCC / 抗体 |
|---|
| Research Abstract |
Malignant pleural mesothelioma (MPM) is an aggressive malignancy. Therefore, novel therapeutic strategies for MPM are urgently necessary for improving the prognosis. In this study, I investigated whether anti-HM1.24 antibody can induce antitumor effects against MPM. Immunostaining showed the expression of HM1.24 of MPM cell lines and malignant mesothelioma tissues. Furthermore, anti-HM1.24 antibody could induce potent ADCC and CDC against HM1.24-positive MPM cells. These results strongly suggest that targeting therapy with therapeutic antibodies might be useful as a novel immunotherapy against MPM.
|
Report
(3 results)
Research Products
(18 results)
-
[Journal Article] A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody2013
Author(s)
Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama SI, Sone S, Minakuchi K, Kato Y, Nishioka Y
-
Journal Title
J Immunol
Volume: 190
Issue: 12
Pages: 6239-6249
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
